Literature DB >> 22527212

[Schnitzler syndrome].

J Loock1.   

Abstract

Schnitzler syndrome is a rare systemic inflammatory disease characterized by the presence of chronic urticarial skin rash and a monoclonal immunoglobulin M (IgM) gammopathy, combined with further, variable disease symptoms. The term refers to a young disease entity which has recently gained increasing acknowledgement and attention, also due to the availability of interleukin-1 (IL-1) blockade as an effective therapeutic option. Insights into the pathophysiology of the disease have resulted in the assumption of Schnitzler syndrome being a special form of an autoinflammatory disease with late onset or an acquired genesis. This article provides an overview on the clinical appearance, current knowledge of pathophysiology and available therapeutic options.

Entities:  

Mesh:

Year:  2012        PMID: 22527212     DOI: 10.1007/s00393-011-0857-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  22 in total

1.  Schnitzler's syndrome: successful treatment of two patients using thalidomide.

Authors:  M Worm; G Kolde
Journal:  Br J Dermatol       Date:  2003-03       Impact factor: 9.302

2.  Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.

Authors:  Victor Manuel Martinez-Taboada; Ana Fontalba; Ricardo Blanco; Jose Luis Fernández-Luna
Journal:  Arthritis Rheum       Date:  2005-07

3.  Another devastating complication of the Schnitzler syndrome: AA amyloidosis.

Authors:  K Claes; B Bammens; M Delforge; P Evenepoel; D Kuypers; Y Vanrenterghem
Journal:  Br J Dermatol       Date:  2007-10-17       Impact factor: 9.302

4.  Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.

Authors:  Heleen D de Koning; Joost Schalkwijk; Jos W M van der Meer; Anna Simon
Journal:  J Allergy Clin Immunol       Date:  2011-06-25       Impact factor: 10.793

5.  Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.

Authors:  H D de Koning; E J Bodar; A Simon; J C H van der Hilst; M G Netea; J W M van der Meer
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

6.  Chronic urticaria and IgG paraproteinaemia: unusual spectrum of Schnitzler Syndrome.

Authors:  M Carlesimo; M La Pietra; A Arcese; D Orsini; G Marmo; L Fidanza; E Mari; G Camplone
Journal:  Clin Ter       Date:  2011

Review 7.  [Schnitzler syndrome: a rare cause of systemic urticaria].

Authors:  P Germain; J Fach; N Bui; T Traissac; X Delbrel; M Le Bras; M Longy-Boursier
Journal:  Rev Med Interne       Date:  2000-03       Impact factor: 0.728

8.  Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin.

Authors:  Bouchra Asli; Boris Bienvenu; Florence Cordoliani; Jean-Claude Brouet; Yurdagul Uzunhan; Bertrand Arnulf; Marion Malphettes; Michel Rybojad; Jean-Paul Fermand
Journal:  Arch Dermatol       Date:  2007-08

9.  Chronic urticaria, arthralgia, raised erythrocyte sedimentation rate and IgG paraproteinaemia: a variant of Schnitzler's syndrome?

Authors:  D Nashan; C Sunderkötter; G Bonsmann; T Luger; S Goerdt
Journal:  Br J Dermatol       Date:  1995-07       Impact factor: 9.302

10.  Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review.

Authors:  Emilio Besada; Hans Nossent
Journal:  Clin Rheumatol       Date:  2010-02-01       Impact factor: 3.650

View more
  1 in total

Review 1.  Schnitzler's syndrome: lessons from 281 cases.

Authors:  Heleen D de Koning
Journal:  Clin Transl Allergy       Date:  2014-12-05       Impact factor: 5.871

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.